PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?Maria Luisa Gasparri, Pierluigi Benedetti Panici, Michael D. Mueller et al.|Geburtshilfe und Frauenheilkunde|2017Cited by 134
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.Marianna Nuti, Paolo Marchetti, Federica Mazzuca et al.|Journal of Clinical Oncology|2017Cited by 5